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Abstract 
Objective This study aims to assess the cost-effectiveness of rotavirus immunization in Indonesia, taking breastfeeding patterns explicitly into account. 
Method An age-structured cohort model was developed for the 2011 Indonesia birth cohort. Next, we compared two strategies, the current situation without rotavirus immunization versus the alternative of a national immunization program. We applied a 5-year time horizon, with 1 monthly analytical cycles for children less than 1 year of age and annually thereafter. Three scenarios were compared to the base-case reflecting the actual distribution over the different breastfeeding modes as present in Indonesia: i.e., the population under 2 years old with (i) 100% exclusive breastfeeding, (ii) 100% partial breastfeeding and (iii) 100% no breastfeeding. Monte Carlo simulations were used to examine the economic acceptability and affordability of the rotavirus vaccination. 
Results Rotavirus immunization would effectively reduce severe cases of rotavirus during the first 5 years of a child’s life. Under the market vaccine price the total yearly vaccine cost would amount to US$ 65 million. The incremental cost per quality-adjusted-life-year (QALY) in the base-case was US$ 174 from the societal perspective. Obviously, it was much lower than the 2011 Indonesian Gross Domestic Product (GDP) per capita of US$ 3,469. Affordability results showed that at the GAVI-subsidized vaccine price, rotavirus vaccination could be affordable for the Indonesian health system. Increased uptake of breastfeeding might slightly reduce cost-effectiveness results. 








Introduction Despite the growing number of diarrheal disease in Indonesia, the burden of rotavirus diarrhea as the major cause of diarrheal disease is poorly documented [1,2]. Indonesia was one of the countries in Asia, which received support from PATH’s Rotavirus Vaccine Program to strengthen the World Health Organization’s (WHO)’s expanded immunization recommendations on promoting the global use of rotavirus vaccines [3]. Since 2001, according to the WHO’s generic protocol, a longitudinal survey of rotavirus infection through the Indonesian Rotavirus Surveillance Network (IRSN) has been conducted in six hospitals in Indonesia [1]. The prospective surveillance in 2006 showed that rotavirus infections were responsible for the majority of severe diarrhea in children under 5 years old occurring throughout the year mainly in children aged between 6-24 months old [1]. Breastfeeding is considered to protect against rotavirus infections [4]. The main component of breast milk that is thought to protect against rotavirus infection is lactadherine [4-6]. The WHO estimated that breastfeeding in accordance with the WHO’s recommendations would save 1.45 million children's lives each year in developing countries due to diarrhea disorders and lower respiratory tract infections [5]. The United Nations Children’s Fund (UNICEF) and the WHO issued a recommendation that children should be breastfed for at least six months to reduce the morbidity and mortality rate [7]. In 2003, the Indonesian government changed the recommended duration of exclusive breastfeeding from four to six months. The Indonesian government needs to assess the economic benefits and health outcomes of such a vaccination program before routine rotavirus immunization can be recommended [8]. In terms of economic and financial perspectives, implementation of rotavirus vaccine should ideally be cost-effective. However, it would be difficult to implement rotavirus immunization in the National Immunization Program (NIP) if the vaccine price is not affordable. Determining the financial resources needed is important to estimate the entire cost or budget impact of the vaccination program, even at the prevailing market price [9]. Up to now, only one economic evaluation study on rotavirus immunization has been conducted in Indonesia [8], suggesting that implementation of rotavirus immunization in National Immunization Program (NIP) would be a cost-effective intervention in Indonesia. However, it only evaluated the use of the 2-dose vaccine while ignoring the potential impacts of the 3-dose vaccine in the NIP. Additionally, the previous study applied the vaccine efficacy in a condition of without breastfeeding and it did not take breastfeeding patterns explicitly into account. Notably, further increasing breastfeeding would be in line with the WHO's recommendations on that matter. However, this might impact the economic evaluation 
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results for rotavirus vaccination as maternal protection would be enhanced leaving less room for the preventive effect of the vaccine. Hence, it is important to know whether potential favorable cost-effectiveness remains within the context of the Indonesian policy to enhance the uptake of breastfeeding. The objective of this study is to assess the cost-effectiveness of rotavirus immunization in Indonesia, taking breastfeeding patterns explicitly into account.  
Methods 
Model Considering the limitations of previous study and motivated by exploring the impact of breastfeeding in childhood vaccination, we performed a cost-effectiveness analysis on rotavirus immunization focusing on the use of Rotateq® as one of the recommended 3-dose rotavirus vaccines. Differing from previous studies on similar topic and model [8,10-13], we explicitly took breastfeeding patterns into account and compared three scenarios to the base-case reflecting the actual distribution over the different breastfeeding modes as present in Indonesia: i.e., the population under 2 years old with (i) 100% exclusive breastfeeding (EBF), (ii) 100% partial breastfeeding (PBF) and (iii) 100% no breastfeeding (NBF). The vaccination program was compared to the condition without vaccination in the situations of the actual breastfeeding pattern (base-case) and specific scenarios.  In this study we applied an age-structured cohort model based on a decision tree model, developed by University of Groningen labeled “Consensus Model on Rotavirus Vaccination” (CoRoVa), which has been used previously for both developing and developed countries [10,11], to assess the cost-effectiveness and affordability of implementing universal rotavirus immunization based on the GAVI-subsidized vaccine price and market vaccine price, in the context of the Indonesian healthcare system for the next 5 years (see Fig. 1). We applied this model because of its ability to account all relevant epidemiological parameters, economic aspects and characteristics of the vaccine, inclusive potential waning immunity [14], and it was also readily available to us. In particular, we used a birth cohort of 4,200,000 infants [8] in this age-structured cohort model and applied a 5-year time horizon with 1 month analytical cycles for children less than 1 year of age and annual cycles beyond 1 year.  
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  Fig. 1. Decision analytic model for estimating the cost-effectiveness of rotavirus immunization in Indonesia   
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assumed that the proportions of breastfeeding population under 2 years old are 100% EBF, 100% PBF and 100% NBF for scenario 1, 2 and 3, respectively. We considered a time horizon of 2 years in our breastfeeding scenario as WHO recommended exclusive breastfeeding for the first six months of life and supplemented breastfeeding continued up to two years or beyond [7]. For 36-47 months, we assumed that the proportions over breastfeeding status are 90% NBF, 10% PBF, 0% EBF, whereas for 48-59 months we assumed 100% NBF. Related to the diarrhea cases in under-5-year-old children, we used 2007 data from a previous study in Indonesia as a base-case [8]. We assumed the same number of diarrhea cases for 2011 as analyzed for 2007. For the scenarios compared, we estimated diarrhea cases explicitly based on breastfeeding distribution. Considering the relative risk of diarrhea from IDHS 2007 and the WHO’s algorithm for calculating relative risk of diarrhea morbidity by feeding mode [16], we estimated 2011 diarrhea cases for under-5-year-old children depending on breastfeeding status for base-case and all scenarios. Secondly, we applied the same approach to calculate 2011 rotavirus-diarrhea cases for under-5-year-old children in base-case and all scenarios by considering the percentage of patients with rotavirus-diarrhea from the number of patients with diarrhea enrolled in each age group from previous study about burden of rotavirus-diarrhea in Indonesia [1]. Finally, we classified rotavirus-diarrhea cases into the four levels of severity by applying proportions of 1.1% for death, 22.9% for hospitalization (severe cases) and 76.0% for outpatient visit (moderate and mild cases) on rotavirus-diarrhea cases [8]. Furthermore, we estimated that moderate would make up 38.7% and mild 61.3% from outpatient visit cases, based on a previously published application of CoRoVa to the South East Asia Region (SEAR) [14]. Notably, we obtained the number of rotavirus-diarrhea cases in four levels of severity adjusted by age for base-case and all scenarios, consistently considering the same age groups in our adjustments (see Fig. 2).  
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  Fig. 2. Scheme for estimation of rotavirus-diarrhea cases in Indonesia  
Vaccine efficacy, waning immunity and between-dose efficacy Rotavirus vaccine efficacy was estimated to be 84% for the prevention of rotavirus-associated hospitalizations, 70% for the prevention of outpatient visits and 76.5% for prevention of deaths [8]. We assumed these percentages as initial effectiveness of the vaccine for the outcomes: severe, mild/moderate and death, respectively. We applied the vaccine effectiveness from a previous study in Indonesia without breastfeeding [8]. We corrected this vaccine effectiveness in our model taking the estimated effect of breastfeeding patterns into account by considering the WHO’s algorithm for calculating relative risks of diarrhea morbidity by feeding mode for all scenarios [16]. We conservatively assumed that vaccine efficacy would exponentially decrease by 11% per year starting after the first year (waning) based on a previous study [11]. To estimate in-between dose efficacy for a 3-dose Rotateq® vaccine, we applied data from a previously published study where the between-dose efficacy is 82% for first and second doses and 84% for second and third doses [11,17,18]. Based on those data, we estimated vaccine effectiveness against fatal cases between first and second doses at 62.7% (0.82 x 76.5%) and between second and third doses at 64.3% (0.84 x 76.5%) [11,17,18]. We applied 
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the same rates of 0.82 and 0.84  to estimate between-dose efficacies for mild, moderate and severe cases [11]. For vaccine coverage, we assumed that Rotateq® vaccine would be administered at the same time with the DPT vaccine in Indonesia based on data from WHO and UNICEF. The 2011 DPT vaccine coverage of 94% would also be applicable for vaccination with Rotateq® [19] (see Table 1).  
Outcome measures In absence of available data on quality-adjusted-life-year (QALY) losses in Indonesia due to rotavirus infection, we estimated the QALY losses in affected infants and children by considering the duration of illness at 4, 8, 11 and 365 days for mild, moderate, severe and fatal cases, respectively, and applying a number of earlier works in SEAR [10,11,14], which were discounted at a 3% rate (see Table 1).  
Costs The analysis was done from both the healthcare perspective (only direct medical costs) and the societal perspective (direct medical, direct non-medical and indirect costs). Direct costs (medication, diagnostics and bed cost), direct non-medical (transportation) and indirect costs (productivity loss due to rotavirus-diarrhea by the caregiver) due to rotavirus-related severe and moderate cases were estimated from hospitalization data and outpatient visit costs from a cost study previously conducted in Indonesia [8]. For mild cases, we estimated direct medical cost from the expenditure per child of oral-rehydration-therapy (ORT) in diarrhea treatment for children less than 5 years of age [20], while for direct non-medical and indirect costs, we applied the same number with moderate cases [8]. We did not include mortality costs in this study to avoid double counting [21]. All cost items were available in 2007 prices and we converted them to 2011 US$ using the underlying growth rate in consumer prices. Based on a 2011 study in Vietnam, the prices of Rotateq® were assumed at US$ 5 per dose and US$ 0.3 per dose for the market price and the GAVI-subsidized price, respectively. We applied these in Indonesia with 2011 setting. We assumed the price in 2011 will be the same for Vietnam and Indonesia. We applied the cost of vaccine administration at US$ 0.5 based on a 2009 study in Indonesia [8]. Obviously, all costs were discounted with a yearly rate of 3% (see Table 1).  
ICER analysis The incremental cost-effectiveness ratio (ICER) was analyzed in the base-case and three other scenarios. We additionally calculated the impacts of market price on each ICER values. 
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We evaluated the results of rotavirus vaccination in Indonesia by using the WHO’s definition on cost-effectiveness of universal immunization according to the GDP per capita, (i) highly cost-effective (less than one GDP per capita); (ii) cost-effective (between 1 and 3 times GDP per capita); and (iii) cost-ineffective (more than 3 times GDP per capita) [22].  
Sensitivity and budget impact analyses We performed several sensitivity analyses in this study including univariate sensitivity and probabilistic analyses [11]. Univariate sensitivity analyses were performed to investigate the effects of different input parameters on cost and health outcomes, by varying each parameter at value of ± 25 % while keeping other parameters constant. Regarding the breastfeeding patterns, we varied from 100% NBF as the worst condition of breastfeeding to 100% EBF  as the best condition of breastfeeding in several scenarios. Probabilistic sensitivity analysis (PSA) was provided by running 5,000 Monte Carlo simulations using @Risk 4.5.4. Distributions associated with input parameters are shown in Table 1. The PSA results are presented in cost-effectiveness acceptability curves (CEACs) from a societal perspective for all scenarios by using two thresholds, ICER at the base-case value and GDP per capita. Based on the distribution of incremental costs and health gains from 5,000 simulations, we evaluated affordability in base-case related to the required budget for vaccination (vaccination costs + treatment costs) from the healthcare perspective to describe the budget impacts on the implementation of rotavirus vaccination.                
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 Table 1 
Parameters used in the economic model 
Parameters Base-case value Distribution References Vaccine coverage Vaccine efficacy   Mild   Moderate   Severe   Death Incidence rates of rotavirus-diarrhea No breastfeeding   Mild   Moderate   Severe   Death Exclusive breastfeeding   Mild   Moderate   Severe   Death Partial breastfeeding   Mild   Moderate   Severe   Death Utility losses   Mild   Moderate   Severe   Death Total medical direct costs per case (healthcare perspective, US$)   Mild   Moderate   Severe Total direct and indirect costs per case (societal perspective, US$)   Mild   Moderate   Severe Total vaccination and administration cost (per child, US$)   3-dose, Market price Discount rate  
94%  70% 70% 84% 76.5%   0.01134 0.00439 0.00473 0.00024  0.00039 0.00015 0.00016 0.00001  0.01140 0.00441 0.00476 0.00024  0.00164 0.00548 0.02110 1.00000   1.44 4.31 41.72   2.81 5.69 56.34   15.50 3% 
Triangular (89%; 94%; 99%)  Triangular (67%; 70%; 74%) Triangular (67%; 70%; 74%) Triangular (80%; 84%; 88%) Triangular (73%; 76.5%; 80%)   Normal (90%CI; 0.01129-0.01138) Normal (90%CI; 0.00436-0.00441) Normal (90%CI; 0.00470-0.00476) Normal (90%CI; 0.00023-0.00025)  Normal (90%CI; 0.00039-0.00040) Normal (90%CI; 0.00015-0.00016) Normal (90%CI; 0.00016-0.00017) Normal (90%CI; 0.000007-0.00001)  Normal (90%CI; 0.01135-0.01144) Normal (90%CI; 0.00438-0.00444) Normal (90%CI; 0.00473-0.00478) Normal (90%CI; 0.00023-0.00025)  Triangular (using 25% lower and upper)     Triangular (1.08; 1.44; 1.80) Triangular (3.23; 4.31; 5.39) Triangular (31.29; 41.72; 52.15)   Triangular (2.11; 2.81; 3.52) Triangular (4.27; 5.69; 7.11) Triangular (42.25; 56.34; 70.42)   Alternative scenario Unvaried 
[19]  [8]      [8, 11, 14]; calculated    [8, 11, 14]; calculated    [8, 11, 14]; calculated    [10, 11, 14]      [20] [8] [8]   [20] [8] [8]   [8,11] [8]  
Results 
Rotavirus cases and cost of illness In the situation representing the actual combination over the different breastfeeding modes as present in Indonesia currently (base-case) and assuming 94% vaccine coverage [19], vaccination of 4,200,000 birth cohort [8] would reduce rotavirus-diarrhea by 237,368 mild cases, 91,861 moderate cases, 117,110 severe cases and 5,450 deaths. Furthermore, it would save 304,433 discounted QALYs and costs due to rotavirus-diarrhea at US$ 5,111,919 and US$ 7,033,814 from the healthcare and societal perspective, respectively. Comparing other scenarios with the base-case, rotavirus vaccination would obviously give the highest reduction of rotavirus cases, QALYs lost and cost-of-illness averted if no uptake of breastfeeding would exist (scenario 3) (see Table 2). 
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 Table 2 
Results from all scenarios  No Vaccination Vaccination i Difference 
Base-case a Number of RV-diarrhea cases e   Mild cases   Moderate cases   Severe cases   Death cases QALYs lost f Cost of illness (healthcare perspective) f,g Cost of illness (societal perspective) f,h 
 918,545 503,190 194,734 209,970 10,651 617,356 $ 9,718,341 $ 13,415,029 
 466,756 265,822 102,873 92,860 5,201 312,923 $ 4,606,422 $ 6,381,216 
 451,789 237,368 91,861 117,110 5,450 304,433 $ 5,111,919 $ 7,033,814 
Scenario 1 b Number of RV-diarrhea cases e   Mild cases   Moderate cases   Severe cases   Death cases QALYs lost f Cost of illness (healthcare perspective) f,g Cost of illness (societal perspective) f,h 
 854,449 468,077 181,146 195,318 9,908 571,519 $ 9,011,051 $ 12,438,698 
 444,551 252,632 97,768 89,186 4,965 298,368 $ 4,413,572 $ 6,112,735 
 409,898 215,446 83,377 106,132 4,943 273,150 $ 4,597,479 $ 6,325,963 
Scenario 2 c Number of RV-diarrhea cases e   Mild cases   Moderate cases   Severe cases   Death cases QALYs lost f Cost of illness (healthcare perspective) f,g Cost of illness (societal perspective) f,h 
 920,141 504,064 195,073 210,335 10,670 618,496 $ 9,736,138 $ 13,439,596 
 476,352 266,173 103,009 92,963 5,208 313,315 $ 4,610,521 $ 6,386,935 
 452,789 237,891 92,064 117,372 5,462 305,182 $ 5,125,616 $ 7,052,661 
Scenario 3 d Number of RV-diarrhea cases e   Mild cases   Moderate cases   Severe cases   Death cases QALYs lost f Cost of illness (healthcare perspective) f,g Cost of illness (societal perspective) f,h 
 1,020,141 558,845 216,273 233,194 11,829 690,006 $ 10,839,814 $ 14,963,091 
 502,108 286,811 110,996 98,725 5,577 336,098 $ 4,909,978 $ 6,803,853 
 518,033 272,035 105,277 134,469 6,252 353,908 $ 5,929,836 $ 8,159,238 a Actual distribution over the different BF patterns b Population under 2 years old with 100 % EBF c Population under 2 years old with 100 % PBF d Population under 2 years old with 100 % NBF e Population under 5 years old f Discounted g Direct medical cost h Direct medical + direct non-medical + indirect costs i Costs are excluding vaccination cost 
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Cost-effectiveness results In the base-case, with a market price of US$ 5 per dose [11], ICERs from the societal perspective (US$ 174) and from the healthcare perspective (US$ 181) are far below the 2011 Indonesian GDP per capita of US$ 3,495 [23]. It strongly suggests that rotavirus immunization is a highly cost-effective intervention for the Indonesian healthcare system according to the WHO’s definition for cost-effectiveness [22]. Regarding the breastfeeding modes, ICERs from scenario 3 are US$ 146 and US$ 153 from the societal perspective and the healthcare perspective, respectively, reflecting the lowest values compared to other breastfeeding modes. With an optimal breastfeeding in under-2-year-old population (scenario 1), cost-effectiveness would increase to US$ 203 and US$ 197 in both perspectives, yet the ICERs are still far under the WHO threshold (see Fig. 3).  
  Fig. 3. Cost-effectiveness value for all scenarios  
Univariate sensitivity analyses The impacts of parameter changes on the ICERs are shown in a tornado chart (see Fig. 4). The results confirmed that the mortality rate, breastfeeding patterns, total severe cost and severe incidence were the most influential parameters in the sensitivity analyses. The cost-effectiveness results were not sensitive to the total moderate cost, moderate incidence, total mild cost and mild incidence.  
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  Fig. 4. Univariate sensitivity analyses  
Cost-effectiveness acceptability curves (CEACs) The CEACs showed that at the threshold ICER of US$ 174 (the base-case value from the societal perspective), the probability for the vaccination program to be cost-effective would be 47%, 0%, 59% and 100% for the base-case and scenarios 1, 2 and 3, respectively. If a US$ 3,495 (GDP per capita) threshold would be used, 100% of simulations resulted in acceptable ICERs for all scenarios and the base-case (see Fig. 5a). From the societal perspective, cost-effectiveness acceptability curves show the probability that universal newborn rotavirus immunization in Indonesia is cost-effective at different cost-effective threshold values [11].  
Affordability curves Fig. 4 shows affordability where rotavirus vaccine is purchased at the market price and when it is subsidized by the GAVI, US$ 0.3 per dose [11]. At the market price or GAVI-subsidized price, affordability curves showed that rotavirus vaccination is affordable (for the birth cohort of 4,200,000) as a function of the budget constraint, from the healthcare perspective. At the budget of US$ 10,175,000 and US$ 64,940,000 for the GAVI-subsidized price and the market price, respectively, vaccination would be 100% affordable. However, it would not be affordable when the budget does not exceed US$ 10,095,000 and US$ 64,860,000 at the GAVI-subsidized price and the market price, respectively (see Fig. 5b).  
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Fig. 5a. Cost-effectiveness acceptability curves from the societal perspective
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Discussion In the absence of vaccination, rotavirus cases under 5 years old are 918,545; 854,449; 920,141 and 1,020,142; for the base-case,  scenario 1, 2 and 3, respectively. Applying vaccine efficacy at 70%; 84% and 76.5% for mild-moderate, severe and fatal cases, respectively, vaccination would decrease rotavirus-diarrhea cases under 5-years-old of 451,789; 409,898; 452,789 and 518,033, respectively. Vaccination also would decrease costs due to rotavirus from the healthcare perspective by US$ 5,111,919; US$ 4,597,479; US$ 5,125,616 and US$ 5,929,836, respectively. From the societal perspective, it would decrease costs due to rotavirus by US$ 7,033,814; US$ 6,325,963; US$ 7,052,661 and US$ 8,159,238. The cost-
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effectiveness analyses yielded ICERs from the societal perspective at US$ 174, US$ 197, US$ 173 and US$ 146, respectively, for the base-case,  scenario 1, 2 and 3. Our assumption that breastfeeding protects young children against rotavirus infections is congruent with other studies [4]. Our results seem similar with a previous study in Indonesia on the same subject [8], confirming that rotavirus vaccination would be a cost-effective public health intervention for Indonesia. This further supports the WHO’s recommendations on universal rotavirus immunization. The sensitivity analyses showed that the mortality rate, breastfeeding patterns, total severe cost and severe incidence were the most influential parameters impacting the cost-effectiveness results. The results on this study reconfirmed the results from previous studies on cost-effectiveness of rotavirus immunization [10,24,25]. A critical review on cost-effectiveness of rotavirus vaccination previously mentioned that the most influential parameter for middle and low income countries is the mortality rate [24]. Shim et al. indicated that breastfeeding would have substantial impacts in the context of exploring impact on the effectiveness of rotavirus vaccines [25]. Additionally, a previous study in the Netherlands mentioned that cost-effectiveness results were sensitive to the cost of hospitalization (severe cases) [10]. Our study provides information for policy makers on the potential introduction of rotavirus immunization into the NIP. At the current market price of US$ 5 per dose, a rotavirus immunization program in Indonesia could be a highly cost-effective intervention according to the WHO’s criteria for cost-effectiveness. Furthermore, when we took uncertainties into account, affordability analysis indicated that there was a significant difference in required funds for rotavirus vaccination in Indonesia under the GAVI-subsidized and market situations. At the GAVI-subsidized price of US$ 0.3 per dose, rotavirus vaccination would not be affordable when the budget does not exceed US$ 12 million, while at the market price of US$ 5 per dose, it would not be affordable when the budget does not exceed US$ 67 million. In fact, the Indonesian government spent approximately US$ 198 million for NIP activities in 2011 [26]. Compared to the total Indonesian government health budget for the whole mandatory immunization program (hepatitis B, BCG, DTP, measles and polio), the required investment by the government for universal rotavirus vaccination in case of no GAVI support would be more than a third. It means that inclusion of rotavirus immunization would be unrealistic if the Indonesian government had to fully finance it by itself without the GAVI support. A solution could be to reduce the vaccine price through subsidy by international organizations. Leaving funds available could enhance implementation of further vaccination programs (e.g., vaccination against Hepatitis A). 
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Notably, the Indonesian government could decide to develop a new rotavirus vaccine by itself. In particular, the Indonesian government is already considering to manufacture a rotavirus vaccine in mass production in Indonesia through Biofarma [27]. This is important for long-term sustainability of vaccine supply as potential GAVI’s support for rotavirus immunization will eventually end and in the future Indonesian government should finance vaccination by itself. It is reassuring though that, even at the market price of US$ 5 per dose, rotavirus vaccination would be a highly cost-effective strategy in Indonesia and that likely the market price of rotavirus vaccine will further decline in the future due to competition among vaccine manufacturing companies. We do not present the first economic analysis of rotavirus vaccination in Indonesia. Next to reinforcing the results of one previous study, our study does have some novelties. In particular, a generic model that was previously applied in both developed and developing countries has shown its worth in both settings. Therefore, this study could be performed while applying the WHO’s recommendations guiding the model design for low income countries. Additionally, our study took breastfeeding explicitly into account. The relationship between breastfeeding and rotavirus infection is well-established and therefore important to be included in the modeling approach. We specifically compared three breastfeeding models in this study. The advantage of including breastfeeding model is the ability to confirm the impact of different breastfeeding patterns in our economic evaluation results. Finally, another difference referred to our application of an age-structured cohort model, which has abilities to capture multiple infections per infected child and waning immunity. Nevertheless, we encountered several limitations in our study. The first limitation of our analysis is the application of a static model, instead of applying a dynamic continuous model that allows the inclusion of herd immunity effects in the analysis. The lack of detailed data hampered the use of a dynamic model in this study. However, if the herd immunity had been included in the analysis, there would be greater impacts of rotavirus vaccination and stronger favorable cost-effectiveness. Another limitation is the lack of specific rotavirus related diarrhea specific incidence data in Indonesia. As we applied 2007 data from previous study and assumed it would be the same with 2011, these assumptions were varied extensively in multiple sensitivity analysis. Finally, treatment costs were only available for 2007 and had to be adjusted to reflect in 2011 values. Obviously, rotavirus vaccination would be more cost-effective if treatment costs of the disease have increased in the meantime. From the health-economic perspective, the Indonesian government should seriously consider the introduction of rotavirus vaccination. Concomitantly, increasing breastfeeding rate could be considered as one of WHO-supported programs. It has been shown that 
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rotavirus vaccination remains cost-effective with increased uptake of breastfeeding. Obviously, hurdles to be successful in implementing vaccination exist, as generally this might be difficult for a developing country as Indonesia with limited resources. Next to vaccine costs, as an archipelago country, extra challenges exist regarding a potential high budget for a self-sustaining storage and delivery system for the vaccine. However, realistic solutions could certainly be found to overcome difficulties, for example through funding from international organizations for developing countries. Hopefully, the results of this study assist policy makers in deciding an optimal and rational strategy to reduce rotavirus infection in children and attain the WHO’s goal on universal rotavirus immunization.  
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